Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.
WILMINGTON, Del., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced...
- Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789...
PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13, 2024, 4:00 PM CEST (10:00 AM EST...
Interim Phase 1 data for its first-in-class, highly selective IV SMARCA2 degrader, PRT3789, selected for an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 in...
Combining a first-in-class, highly selective SMARCA2 degrader with an anti-PD-1 therapy may potentially enhance the anti-tumor activity of either agent because of the complementary nature of the...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.0024 | 0.126315789474 | 1.9 | 2.08 | 1.82 | 129498 | 1.96818085 | CS |
| 4 | -3.1176 | -62.1035856574 | 5.02 | 5.075 | 1.82 | 420457 | 2.46317234 | CS |
| 12 | -3.3576 | -63.8326996198 | 5.26 | 6.8 | 1.82 | 276945 | 3.85274185 | CS |
| 26 | -3.0376 | -61.4898785425 | 4.94 | 6.8 | 1.82 | 167401 | 3.99837363 | CS |
| 52 | -0.8376 | -30.5693430657 | 2.74 | 6.8 | 1.66 | 154446 | 3.62819763 | CS |
| 156 | -13.9876 | -88.0276903713 | 15.89 | 20.1099 | 1.66 | 169586 | 7.33625238 | CS |
| 260 | -23.8576 | -92.6149068323 | 25.76 | 95.375 | 1.66 | 191172 | 19.04159639 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
